⌘K
Loading ticker…
As of 2026-08-21, Rein Therapeutics, Inc. Common Stock (RNTX) has a 3-month relative strength percentile of 18 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.2%, relative volume 1.24×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RNTX is in a stage 4 downtrend, week 10. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -6.5% / -31.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
RNTX appears in 1 ETF as of May 2026: ONEQ at 0.00% weight, $84K notional.
Held by 4 ETFs · $1M across latest filings · largest weight 0.01% (IWC).
Top 1 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| ONEQ | 0.00% | $84K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RNTX Jan avg: 7.07% median: 7.07% win: 100% σ: 7.07% n: 2 2025-01-14 → 2026-07-31 | RNTX Feb avg: -3.11% median: -3.11% win: 50% σ: 13.01% n: 2 2025-01-14 → 2026-07-31 | RNTX Mar avg: -0.64% median: -0.64% win: 50% σ: 20.75% n: 2 2025-01-14 → 2026-07-31 | RNTX Apr avg: 0.42% median: 0.42% win: 50% σ: 5.39% n: 2 2025-01-14 → 2026-07-31 | RNTX May avg: -2.02% median: -2.02% win: 50% σ: 22.71% n: 2 2025-01-14 → 2026-07-31 | RNTX Jun avg: -17.26% median: -17.26% win: 0% σ: 15.48% n: 2 2025-01-14 → 2026-07-31 | RNTX Jul avg: -22.94% median: -22.94% win: 0% σ: 8.71% n: 2 2025-01-14 → 2026-07-31 | RNTX Aug avg: 19.31% median: 19.31% win: 100% σ: 0.00% n: 1 2025-01-14 → 2026-07-31 (current) | RNTX Sep avg: -17.63% median: -17.63% win: 0% σ: 0.00% n: 1 2025-01-14 → 2026-07-31 | RNTX Oct avg: 36.68% median: 36.68% win: 100% σ: 0.00% n: 1 2025-01-14 → 2026-07-31 | RNTX Nov avg: 0.32% median: 0.32% win: 100% σ: 0.00% n: 1 2025-01-14 → 2026-07-31 | RNTX Dec avg: -26.11% median: -26.11% win: 0% σ: 0.00% n: 1 2025-01-14 → 2026-07-31 |